Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B, while Libtayo sales surged 50% to $367M. Sanofi collaboration revenue also increased.

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo was approved by the US Food and Drug Administration (FDA) as a first-line (1L) therapy for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. On World Cancer ...

The trial is testing the hypothesis that low doses of THIO administered prior to cemiplimab (Libtayo ®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not ...

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the organization’s priorities for the coming year. The Skin Cancer Foundation (SCF), a ...